David Lemus - 30 Aug 2021 Form 4 Insider Report for Sorrento Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 30 Aug 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Aug 2021, 20:13:44 UTC
Next SEC filing: 15 Nov 2022
Source filing: View source filing
Reporting owner signature: /s/ Henry Ji, Ph.D., as attorney-in-fact

Key filing fact

David Lemus filed Form 4 for Sorrento Therapeutics, Inc. on 30 Aug 2021.

Key facts

This page summarizes David Lemus's Form 4 filing for Sorrento Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Aug 2021, 20:13.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SRNEQ transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 30 Aug 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $8.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the original number of shares subject to this option shall vest and become exercisable on September 30, 2021, and 1/48th of the original number of shares subject to the option shall vest following each one month of service thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.